The global erythromelalgia treatment market size was valued at USD 1.37 billion in 2024 and is expected to reach USD 1.80 billion by 2032, at a CAGR of 3.50% during the forecast period
The market growth is largely fueled by increasing awareness of rare vascular disorders, advancements in targeted therapies, and the expansion of personalized medicine approaches, driving adoption of effective treatment options
Furthermore, rising patient demand for safe, rapid-acting, and symptom-specific therapies, along with supportive healthcare initiatives and improved diagnostic capabilities, is positioning novel and conventional treatments as the preferred choice. These converging factors are accelerating the adoption of erythromelalgia therapies, thereby significantly boosting the industry’s growth